This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Ablynx N.v.. Active years: 2018-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2021
Title: Stefaan Rossenu: Innovator in Rheumatoid Arthritis Treatment
Introduction
Stefaan Rossenu is a notable inventor based in Lovendegem, Belgium. He has made significant contributions to the field of medicine, particularly in the treatment of rheumatoid arthritis. With a total of 2 patents to his name, Rossenu's work focuses on innovative methods that enhance patient care and treatment efficacy.
Latest Patents
Rossenu's latest patents include a method for treating rheumatoid arthritis by administering IL-6 receptor antibodies. This invention provides polypeptides directed against IL-6R at specific dose ranges and dosing schedules, resulting in a prolonged effect on IL-6 mediated signaling. The invention offers pharmacologically active agents, compositions, methods, and dosing schedules that present advantages over existing treatments. Notably, it allows for less frequent dosing or lower doses to achieve equivalent effects in inhibiting IL-6 mediated signaling. Another patent by Rossenu also addresses methods for treating rheumatoid arthritis using interleukin-6 receptor antibodies, reinforcing his commitment to improving therapeutic options for patients.
Career Highlights
Stefaan Rossenu is associated with Ablynx N.V., a company known for its innovative biopharmaceuticals. His work at Ablynx has positioned him as a key player in the development of novel treatments for autoimmune diseases.
Collaborations
Rossenu collaborates with talented professionals in his field, including Josefin-Beate Holz and Steven De Bruyn. These partnerships enhance the research and development efforts at Ablynx, contributing to the advancement of medical science.
Conclusion
Stefaan Rossenu's contributions to the treatment of rheumatoid arthritis through his innovative patents demonstrate his dedication to improving patient outcomes. His work continues to influence the field of biopharmaceuticals, paving the way for future advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile